Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of Amivantamab Infusion Related Reaction Mitigation
2022-000974-25Phase 2Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of amivantamab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Rate of infusion-related reactions on Cycle 1 Day 1. Started Dec 2022; status: active.
02
Drugs
amivantamab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2022-000974-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000974-25.